Skip to content
HowShorted

Puma Biotechnology Inc short interest in 2019

In 2019, Puma Biotechnology Inc's disclosed short interest ran from 11.78% of shares outstanding on 15 Jan 2019 to 17.86% on 31 Dec 2019, a change of +6.08 percentage points. The year's high was 22.96% on 13 Sep 2019 and its low 9.85% on 29 Mar 2019, averaging 16.09% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.69 days on 15 Feb 2019. Full history: Puma Biotechnology Inc.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Puma Biotechnology Inc in 2019

2019 in figures

Start of year
11.78% (15 Jan 2019)
End of year
17.86% (31 Dec 2019)
Change
+6.08 pp
High
22.96% (13 Sep 2019)
Low
9.85% (29 Mar 2019)
Average
16.09%
Highest days to cover
8.69 (15 Feb 2019)
SEC filings marked
8

Every report in 2019

Puma Biotechnology Inc short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201911.78%4.23
31 Jan 201913.65%5.79
15 Feb 201913.00%8.69
28 Feb 201912.18%4.40results (8-K)
15 Mar 201912.54%2.1310-K filed
29 Mar 20199.85%5.28
15 Apr 201912.44%6.07
30 Apr 201911.40%7.02
15 May 201910.74%2.11results (8-K), 10-Q filed
31 May 201911.24%4.77
14 Jun 201910.18%3.97
28 Jun 201917.71%3.90
15 Jul 201919.53%7.60
31 Jul 201919.01%5.67
15 Aug 201922.77%4.20results (8-K), 10-Q filed
30 Aug 201922.74%8.30
13 Sep 201922.96%5.91
30 Sep 201921.00%4.99
15 Oct 201921.05%4.51
31 Oct 201919.81%5.68
15 Nov 201917.00%3.56results (8-K), 10-Q filed
29 Nov 201917.49%5.05
13 Dec 201918.17%3.03
31 Dec 201917.86%4.57

See also: Puma Biotechnology Inc's full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.